PHOENIX (Feb. 11, 2019)– Retinal Consultants of Arizona & the Retinal Research Institute – one of the nation’s leading retina & vitreous clinical research and patient treatment facilities – is proud to announce that Dr. Pravin U. Dugel has conducted the first stem cell therapy treatment for patients with retinitis pigmentosa (RP) in Arizona. The… Read More »
Graybug Vision Presents Top Line Results of Phase 1/2a ADAGIO Study at Hawaiian Eye & Retina 2019 ADAGIO Study Provides Evidence that GB-102 Can Achieve Sustained-Drug Delivery in the Treatment of Wet Age-Related Macular Degeneration (AMD) Graybug Vision’s novel investigational depot approach is designed to continuously inhibit activity of all VEGF receptors for the treatment… Read More »
An Independent Analysis of Protocol i Study Data Dugel, Pravin U., MD*,†; Campbell, Joanna H., PhD‡; Kiss, Szilárd, MD§; Loewenstein, Anat, MD¶; Shih, Vanessa, PharmD‡; Xu, Xiaoshu, MS‡; Holekamp, Nancy M., MD**; Augustin, Albert J., MD, PhD††; Ho, Allen C., MD‡‡; Gonzalez, Victor H., MD§§; Whitcup, Scott M., MD¶¶ RETINA: January 2019 – Volume 39… Read More »
Neovascular age-related macular degeneration (nAMD) is the leading cause of severe vision loss and irreversible blindness in people aged over 65 years in North America, Europe, Australia, and Asia.1 Anti-vascular endothelial growth factor (anti-VEGF) therapies have led to great improvements in outcomes for patients with nAMD.2 However, currently available anti-VEGF treatments require frequent clinic visits to monitor… Read More »
American Academy of Ophthalmology (AAO) Annual Meeting: HAWK AND HARRIER Trials Reaffirm Direction for a Novel Anti-VEGF Dr. Dugel has authored more than 200 papers, 35 book chapters and has been invited to lecture at prestigious meetings, Visiting Professorships and Universities worldwide, including Japan, India, China, Malaysia, Egypt, United Kingdom, France, Germany, Austria, Italy, Poland,… Read More »
Retina Subspecialty Day Coverage – American Academy of Ophthalmology 2018 Series: 2018 Pravin U. Dugel, MD Channels: Retina Pravin U. Dugel, MD, details the results of the phase 3 HAWK and HARRIER studies evaluating brolucizumab (Novartis) for the treatment of wet age-related macular degeneration. Dr. Dugel compares data from the 96-week endpoint to the… Read More »
Intravitreal Interventions: Volume 7, Number 4 Click Here to Start Author(s)/Faculty: Rishi P. Singh, MD; Ahmad Al-Moujahed, MD, MPH; Sarina M. Amin, MD; Malvika Arya, BS; Pravin U. Dugel, MD; Jorge A. Fortun, MD; Andrew A. Moshfeghi, MD, MBA; Nadia K. Waheed, MD, MPH Release Date: 10/30/2018 Expiration Date: 10/29/2019 Credit Type: CME Number… Read More »
October 27, 2018 10:09 ET | Source: Novartis International AG Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in central subfield thickness demonstrated at year one were reaffirmed at year two with brolucizumab 6 mg versus aflibercept Robust visual gains shown in… Read More »
At this year’s EURETINA congress, we caught up with Dr Pravin Dugel to discuss neovascular age-related macular degeneration (nAMD). Dr Dugel suggests that while there have been recent advances in the treatment of nAMD, there is still a need to obtain better efficacy and find drugs that maintain visual acuity improvement over the… Read More »
Lausanne, Switzerland, September 24th, 2018 – Oculis, a clinical-stage biotechnology company developing next-generation topical treatments for acute and chronic back- and front-of-the-eye diseases, announces the appointment of Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board (SAB). Dr. Dugel is internationally recognized for his research in the field of ophthalmologic diseases and brings… Read More »
